Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: Fact or fiction?

AIDS

Volumn 26, Issue 17, 2012, Pages 2193-2199

  Solas, Caroline ^a,b   Pambrun, Elodie ^c   Winnock, Maria ^c   Salmon, Dominique ^d   Poizot Martin, Isabelle ^b   Dominguez, Stéphanie ^e   Bani Sadr, Firouzé ^f   Izopet, Jacques ^g   Garraffo, Rodolphe ^h   Peytavin, Gilles ⁱ  

^a University of the Mediterranean Aix Marseille II   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

^d ISPED ^*  (France)

^e HENRI MONDOR HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g CHU PURPAN   (France)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ BICHAT HOSPITAL   (France)

Author keywords

abacavir; drug interaction; HIV HCV co infection; ribavirin; virological response

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84869504347     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835763a4     Document Type: Article

References (23)

1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
2. Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, et al. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18:e52- e60.
3. Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations and HCV-RNA load. J Hepatol 2012; 56:788-794.
4. Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus coinfection. AIDS 2007; 21:1555-1559.
5. Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P, The French Ribavirin Group OPTIRIB. Ribavirin therapeutic drug monitoring: why, when and how? Fund Clin Pharmacol 2010; 24:401-406.
6. Solas C, Paré M, Quaranta S, Stanke-Labesque F. Evidencebased therapeutic drug monitoring for ribavirine. Therapie 2011; 66:221-230.
7. Morello J, Rodríguez-Novoa S, Jiménez-Nácher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62:1174- 1180.
8. Vogel M, Rockstroh J. The treatment of chronic hepatitis C virus infection in HIV co-infection. Eur J Med Res 2009; 14:507-515.
9. Yéni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. La Documentation Française; 2010; pp. 265-280.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; pp. 1-167. Http://www.aidsinfo. nih. gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed on 12 December 2011].
11. Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010; 10:303.
12. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615- 624.
13. Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125.
14. Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
15. Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437.
16. Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354.
17. Laufer N, Laguno M, Perez I, Cifuentes C, Murillas J, Vidal F, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953-957.
18. Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010; 15:91-99.
19. Moreno A, Quereda C, Muriel A, Pérez-Elias MJ, Casado JL, Donda F, et al. Does the choice of NRTIs have a significant influence on the outcome of peg-IFN plus ribavirin among HIV/HCV-co-infected patients? [abstract]. In: Program and abstract of 15th Conference on Retroviruses and Opportunistic Infections. Boston, 3-6 February 2008; p. A1075
20. Berenguer J, von Wichmann M, Quereda C, Miralles P, Malolas J, Lopez Aldeguer J, et al. Effects of accompanying antiretroviral drugs on virologic response to PEG-IFN and ribavirin in HIV/HCV co-infected patients [abstract. In: Program and abstract of 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, 16-19 February 2010; p. A663
21. Cassard B, Poizot-Martin I, Solas C, Tubiana R, Valentin M, Levy Y, et al. Early therapeutic drug monitoring of ribavirin is predictive of tolerability andearly and sustained virological response in HIV-HCV co-infected patients [abstract.] In: Program and abstract of 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy. New Orleans 9-10 April 2008: A05
22. Margot NA, Miller MD. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther 2005; 10:343-348.
23. Van den Eynde E, Quer J, Cubero M, Curran A, Homs M, Garcia- Cehic D, et al. Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system. Antivir Ther 2011; 16:887-893.